Urea-mediated cross-presentation of soluble epstein-barr virus BZLF1 protein

PLoS Pathogens

Volumn 4, Issue 11, 2008, Pages

  Barabas, Sascha ^a   Gary, Regina ^b   Bauer, Tanja ^a   Lindner, Juha ^a   Lindner, Petra ^a   Weinberger, Birgit ^c   Jilg, Wolfgang ^a   Wolf, Hans ^a   Deml, Ludwig ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; PEPTIDE; PROTEASOME; TRANSCRIPTION FACTOR ETV6; UREA; VIRUS PROTEIN; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; HLA ANTIGEN CLASS 1; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; EPSTEIN BARR VIRUS; HLA SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; TECHNOLOGY; TEMPERATURE DEPENDENCE; CELL CULTURE; CHEMISTRY; CROSS PRESENTATION; IMMUNOLOGY; SOLUBILITY; TECHNIQUE; VIROLOGY;

HUMAN HERPESVIRUS 4;

ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CELLS, CULTURED; CROSS-PRIMING; DENDRITIC CELLS; ENDOCYTOSIS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; METHODS; MONOCYTES; SOLUBILITY; TRANS-ACTIVATORS; UREA;

EID: 57149091126     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000198     Document Type: Article

References (53)

1. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
2. Goldberg AL, Rock KL (1992) Proteolysis, proteasomes and antigen presentation. Nature 357: 375-379.
3. Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23: 975-1028.
4. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 90: 4942-4946.
5. Huang S, Terstappen LW (1994) Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38+ hematopoietic stem cells. Blood 83: 1515-1526.
6. Sigal LJ, Crotty S, Andino R, Rock KL (1999) Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398: 77-80.
7. Heit A, Huster KM, Schmitz F, Schiemann M, Busch DH, et al. (2004) CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 172: 1501-1507.
8. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, et al. (2000) Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 6: 1348-1354.
9. Tvinnereim AR, Hamilton SE, Harty JT (2004) Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens. J Immunol 173: 1994-2002.
10. Rock KL (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17: 131-137.
11. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1: 362-368.
12. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, et al. (2000) Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 191: 1957-1964.
13. Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, et al. (1999) Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci U S A 96: 10326-10331.
14. Lindner J, Barabas S, Saar K, Altmann D, Pfister A, et al. (2005) CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection. J Vet Med B Infect Dis Vet Public Health 52: 356-361.
15. Ribas A (2005) Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 5: 619-628.
16. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, et al. (2006) The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A 103: 10729-10734.
17. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195: 125-133.
18. Schnurr M, Chen Q, Shin A, Chen W, Toy T, et al. (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465-2472.
19. Stittelaar KJ, Hoogerhout P, Ovaa W, van Binnendijk RR, Poelen MC, et al. (2001) In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine 20: 249-261.
20. Javid B, Macary PA, Lehner PJ (2007) Structure and function: heat shock proteins and adaptive immunity. J Immunol 179: 2035-2040.
21. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193.
22. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258.
23. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I (2003) Activation of lysosomal function during dendritic cell maturation. Science 299: 1400-1403.
24. Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W (1995) Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol 69: 4872-4879.
25. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307: 593-596.
26. Kalish RS, Koujak S (2004) Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. Clin Immunol 113: 270-277.
27. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, et al. (2006) Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203: 995-1006.
28. Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K (2003) Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J Immunol 170: 2590-2598.
29. Blake N, Lee S, Redchenko I, Thomas W, Steven N, et al. (1997) Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7: 791-802.
30. Blake N, Haigh T, Shaka'a G, Croom-Carter D, Rickinson A (2000) The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 165: 7078-7087.
31. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, et al. (1998) Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4: 1449-1452.
32. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521.
33. Shi Y, Galusha SA, Rock KL (2006) Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol 176: 3905-3908.
34. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K (2003) Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278: 35109-35114.
35. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
36. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, et al. (1998) Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 16: 857-861.
37. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A 88: 1864-1868.
38. Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10: 310-315.
39. Kaplan IM, Wadia JS, Dowdy SF (2005) Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102: 247-253.
40. Delneste Y, Magistrelli G, Gauchat J, Haeuw J, Aubry J, et al. (2002) Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17: 353-362.
41. Jutras I, Desjardins M (2005) Phagocytosis: at the crossroads of innate and adaptive immunity. Annu Rev Cell Dev Biol 21: 511-527.
42. Daukas G, Zigmond SH (1985) Inhibition of receptor-mediated but not fluid-phase endocytosis in polymorphonuclear leukocytes. J Cell Biol 101: 1673-1679.
43. Johannes L, Tenza D, Antony C, Goud B (1997) Retrograde transport of KDEL-bearing B-fragment of Shiga toxin. J Biol Chem 272: 19554-19561.
44. Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Strominger JL, et al. (1999) Extracellular antigen processing and presentation by immature dendritic cells. Proc Natl Acad Sci U S A 96: 15056-15061.
45. Ackerman AL, Cresswell P (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5: 678-684.
46. Hon H, Oran A, Brocker T, Jacob J (2005) B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 174: 5233-5242.
47. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, et al. (2006) Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117: 78-88.
48. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621-667.
49. Norbury CC (2006) Drinking a lot is good for dendritic cells. Immunology 117: 443-451.
50. Cresswell P (2004) Cell biology. Cutting and pasting antigenic peptides. Science 304: 525-527.
51. Wild J, Bojak A, Deml L, Wagner R (2004) Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model. Vaccine 22: 1732-1743.
52. Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, et al. (2003) Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol 170: 5406-5413.
53. Bauer T, Gunther M, Bienzle U, Neuhaus R, Jilg W (2007) Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl 13: 434-442.